Icon

GEMZAR (nda020509)- (EQ 200MG BASE/VIAL,EQ 1GM BASE/VIAL)

GEMCITABINE HYDROCHLORIDE LILLY
EQ 200MG BASE/VIAL,EQ 1GM BASE/VIAL
Yes No
2013-May-07 Expired
None None
None No
GEMZAR® is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. • in combination with cisplatin, for the treatment of non-small cell lung cancer. • as a single agent for the treatment of pancreatic cancer.
10 2 6
Total Other Developers None
Drugs with Suitability No
EQ 200MG BASE/VIAL ** ** - - -
EQ 1GM BASE/VIAL ** ** - - 5
NDA Sales Available Total Generic Sales Available
No 5
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ********* **** *** ********* **** ***, *** *********** **** *. **** ****** **** ***** ********* ******, ******* ****, ******** (**) *****, ****** ****** (***) ***
****** ** ****** **** *** **.*****'* ************ ******* *********** ** ** ** & ** ** **, ***** - ***, ****, *******,, *************, ****** ******* *** ***, ***** (***) ***
****** ** ****** **** *** ***** ******* *********** **** ** ****, *-*** ** *-***, *-*** ** *-***, **** ** *-***/*/*/*, *-****, *-***, *-***, *-***, ***** ********** ****, ********, *** ******, ***** (***) ***
****** ** ****** **** *** ****** *************** **., ***. *********** **.*-* ***** ****, ******* **-**** ************* ****** ****, *******, ******* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. * ** **, *******, **** ******* ******, *******-***** *******, **. *-*, ****** ******, *********, ******* ******, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** **** * & **** **, ***** *, ***** *, ************* ******* ******** **** (**** ), *******, *************, ****** ******* ******, ***** (***) ***
****** ***** **** ****** ********** **** ********* *********** ************ **, **********, ***** ****** *****, ******* (***) ***
****** ******* ******* ********* *** *** *********** *-** ***** **, ********, ******** ****, ********* (***) ***
****** ******* ***** ******* ******** ******* ******* *********** **** **.*, *******, ******* ******** ****, ******* ***** *******, ******* ******, ****** ******, *********, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.